Latest Contribution
Intravitreal Ziv-Aflibercept: safety analysis
Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...
Treat-and-extend regimen in treatment of patients with type 3 neovascularisation
Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...
Sutureless, scleral fixated-IOLs
This was a retrospective cohort study of 112 sutureless, scleral-fixated posterior chamber intraocular lens implantations (SSFCIOL) over a four-year time period. Mean follow-up duration was 13.0 ±10.4 months. The primary indication for SSFCIOL was dislocation of IOL due to zonular...
